Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 15, 2015 - Issue 12
Submit an article Journal homepage
2,140
Views
19
CrossRef citations to date
0
Altmetric
Editorial

Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma

Francesco MassariMedical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy
,
Chiara CiccareseMedical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy
,
Matteo SantoniClinica di Oncologia Medica, AOU Ospedali Riuniti, Polytechnic University of Marche, Ancona, Italy
,
Antonio Lopez-BeltranDepartment of Surgery, Cordoba University Medical School, Cordoba, Spain
,
Marina ScarpelliSection of Pathological Anatomy, Polytechnic University of the Marche Region, Ancona, Italy
,
Rodolfo MontironiSection of Pathological Anatomy, Polytechnic University of the Marche Region, Ancona, Italy
&
Liang ChengDepartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA;Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USACorrespondence[email protected]
 show all
Pages 1367-1369 | Published online: 14 Nov 2015

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Chiara Ciccarese, Vincenzo Di Nunno, Rodolfo Montironi, Michelangelo Fiorentino, Matteo Brunelli, Giampaolo Tortora, Andrea Ardizzoni & Francesco Massari. (2016) The role of precision medicine for the treatment of metastatic renal cell carcinoma. Expert Review of Precision Medicine and Drug Development 1:4, pages 369-377.
Read now

Articles from other publishers (18)

Hanneke van der Wijngaart, Robin Beekhof, Jaco C. Knol, Alex A. Henneman, Richard de Goeij-de Haas, Sander R. Piersma, Thang V. Pham, Connie R. Jimenez, Henk M. W. Verheul & Mariette Labots. (2023) Candidate biomarkers for treatment benefit from sunitinib in patients with advanced renal cell carcinoma using mass spectrometry-based (phospho)proteomics. Clinical Proteomics 20:1.
Crossref
Murali Ragothaman & So Young Yoo. (2023) Engineered Phage-Based Cancer Vaccines: Current Advances and Future Directions. Vaccines 11:5, pages 919.
Crossref
Nidhi Dwivedi, Abeda Jamadar, Sijo Mathew, Timothy A. Fields & Reena Rao. (2023) Myofibroblast depletion reduces kidney cyst growth and fibrosis in autosomal dominant polycystic kidney disease. Kidney International 103:1, pages 144-155.
Crossref
Bilin Liang, Haifan Gong, Lu Lu & Jie Xu. (2022) Risk stratification and pathway analysis based on graph neural network and interpretable algorithm. BMC Bioinformatics 23:1.
Crossref
Abeda Jamadar, Nidhi Dwivedi, Sijo Mathew, James P. Calvet, Sufi M. Thomas & Reena Rao. (2022) Vasopressin Receptor Type-2 Mediated Signaling in Renal Cell Carcinoma Stimulates Stromal Fibroblast Activation. International Journal of Molecular Sciences 23:14, pages 7601.
Crossref
Naglaa M. El-Lakkany, Hadeel H. Elkattan & Alaa E. Elsisi. (2021) The ponatinib/gossypol novel combination provides enhanced anticancer activity against murine solid Ehrlich carcinoma via triggering apoptosis and inhibiting proliferation/angiogenesis. Toxicology and Applied Pharmacology 432, pages 115767.
Crossref
Annamaria Aloisio, Nancy Nisticò, Selena Mimmi, Domenico Maisano, Eleonora Vecchio, Giuseppe Fiume, Enrico Iaccino & Ileana Quinto. (2021) Phage-Displayed Peptides for Targeting Tyrosine Kinase Membrane Receptors in Cancer Therapy. Viruses 13:4, pages 649.
Crossref
Jingbo Zhang, Yunchao Liu, Bing Xu, Fuwei Li, Yan Wang, Mengjian Li, Rong Du, Ye Zhou, Meghan Salgia, Lixin Yang & Jeremy Jones. (2020) Circulating tumor DNA analysis of metastatic renal cell carcinoma. Molecular and Clinical Oncology 14:1.
Crossref
Sergei Boichuk, Aigul Galembikova, Ekaterina Mikheeva, Firuza Bikinieva, Aida Aukhadieva, Pavel Dunaev, Dinar Khalikov, Semen Petrov, Refat Kurtasanov, Elena Valeeva, Igor Kireev, Vera Dugina, Anna Lushnikova, Maria Novikova & Pavel Kopnin. (2020) Inhibition of FGF2-Mediated Signaling in GIST—Promising Approach for Overcoming Resistance to Imatinib. Cancers 12:6, pages 1674.
Crossref
Jianhui Ma, Yan Song, Jianzhong Shou, Yuxian Bai, Hanzhong Li, Xiaodong Xie, Hong Luo, Xiubao Ren, Jiyan Liu, Dingwei Ye, Xianzhong Bai, Cheng Fu, Shukui Qin, Jinwan Wang & Ai-Ping Zhou. (2020) Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial. Frontiers in Oncology 10.
Crossref
José A. Jiménez-Torres, María Virumbrales-Muñoz, Kyung E. Sung, Moon Hee Lee, E. Jason Abel & David J. Beebe. (2019) Patient-specific organotypic blood vessels as an in vitro model for anti-angiogenic drug response testing in renal cell carcinoma. EBioMedicine 42, pages 408-419.
Crossref
Viktor Grünwald, Thomas Powles, Toni K Choueiri, Thomas E Hutson, Camillo Porta, Masatoshi Eto, Cora N Sternberg, Sun Young Rha, Cixin S He, Corina E Dutcus, Alan Smith, Lea Dutta, Kalgi Mody & Robert J Motzer. (2019) Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. Future Oncology 15:9, pages 929-941.
Crossref
Qi Hui, Zi Jin, Xiaokun Li, Changxiao Liu & Xiaojie Wang. (2018) FGF Family: From Drug Development to Clinical Application. International Journal of Molecular Sciences 19:7, pages 1875.
Crossref
Nizar M. Tannir, Sumanta K. Pal & Michael B. Atkins. (2018) Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review. The Oncologist 23:5, pages 540-555.
Crossref
Meghan Salgia, Jacob Adashek, Paulo Bergerot & Sumanta K. Pal. (2017) Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice. Kidney Cancer 1:2, pages 99-105.
Crossref
Sherry Bhalla, Kumardeep Chaudhary, Ritesh Kumar, Manika Sehgal, Harpreet Kaur, Suresh Sharma & Gajendra P. S. Raghava. (2017) Gene expression-based biomarkers for discriminating early and late stage of clear cell renal cancer. Scientific Reports 7:1.
Crossref
Chiara Ciccarese, Matteo Brunelli, Rodolfo Montironi, Michelangelo Fiorentino, Roberto Iacovelli, Daniel Heng, Giampaolo Tortora & Francesco Massari. (2016) The prospect of precision therapy for renal cell carcinoma. Cancer Treatment Reviews 49, pages 37-44.
Crossref
Anne Close. (2016) Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility. Future Medicinal Chemistry 8:4, pages 443-462.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.